Breaking News

Retrospective cohort study on the impact of biologics on medical resource use, cost and outcomes in psoriasis patients

Retrospective cohort study on the impact of biologics on medical resource use, cost and outcomes in psoriasis patients

 
 

The impact on the use of UK medical resources, costs and outcomes associated with the introduction of biological therapies (adalimumab, etanercept or infliximab) in patients with moderate-severe psoriasis was collated. Data were obtained from a sequential patient cohort for 12 months prior to and at least 6 months following initiation of treatment. Clinical outcomes were measured by the Psoriasis Area and Severity Index (PASI). The analysis comprised 76 patients completing 12 months of therapy; their mean age was 47 years (range 23-74) with a mean psoriasis duration of 26 years. Mean annual costs decreased by £1,682 (P = 0.028), while mean annual drug costs rose by £9,456 and the mean PASI ...

 
to Continue Reading, Login Now
 

Please Login

 
 
  
 
 
If you are a registered user but you have forgotten your password, please click here
 
If you are not a registered user, please register here

return to breaking news list